CAS Medical's laser-based neonatal cerebral oximeter
This article was originally published in Clinica
Executive Summary
The Fore-Sight cerebral oximeter developed by CAS Medical Systems has received US FDA 510(k) clearance to be used in newborn babies weighing more than 2.5kg. The noninvasive device detects low cerebral oxygen saturation events using Branford, Connecticut-based CAS Medical's Laser-Sight technology. This works on the basis that blood contains both oxygenated and de-oxygenated haemoglobin; the two forms of haemoglobin absorb light in different, measurable ways. Laser light is projected through the scalp and skull and into the brain to detect levels of oxy and de-oxy haemoglobin. The reflected light is captured by a sensor and is analysed to determine cerebral tissue oxygen saturation. US launch of the Fore-Sight sensor is planned for the second half of 2008.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.